- Home
- TD vs VRTX Comparison
TD vs VRTX Comparison
Compare TD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TD
- VRTX
- Stock Information
- Founded
- TD 1855
- VRTX 1989
- Country
- TD Canada
- VRTX United States
- Employees
- TD N/A
- VRTX N/A
- Industry
- TD
- VRTX EDP Services
- Sector
- TD
- VRTX Technology
- Exchange
- TD Nasdaq
- VRTX Nasdaq
- Market Cap
- TD 112.5B
- VRTX 115.6B
- IPO Year
- TD N/A
- VRTX 1991
- Fundamental
- Price
- TD $69.04
- VRTX $442.05
- Analyst Decision
- TD Buy
- VRTX Buy
- Analyst Count
- TD 2
- VRTX 26
- Target Price
- TD $91.50
- VRTX $512.54
- AVG Volume (30 Days)
- TD 1.6M
- VRTX 2.2M
- Earning Date
- TD 05-22-2025
- VRTX 05-05-2025
- Dividend Yield
- TD 4.24%
- VRTX N/A
- EPS Growth
- TD 63.11
- VRTX N/A
- EPS
- TD 6.97
- VRTX N/A
- Revenue
- TD $45,024,677,580.00
- VRTX $11,099,700,000.00
- Revenue This Year
- TD $9.41
- VRTX $10.36
- Revenue Next Year
- TD $3.90
- VRTX $10.61
- P/E Ratio
- TD $9.74
- VRTX N/A
- Revenue Growth
- TD 20.69
- VRTX 8.98
- 52 Week Low
- TD $51.25
- VRTX $377.85
- 52 Week High
- TD $69.30
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- TD 81.02
- VRTX 43.63
- Support Level
- TD $64.12
- VRTX $427.43
- Resistance Level
- TD $68.74
- VRTX $451.64
- Average True Range (ATR)
- TD 0.89
- VRTX 10.29
- MACD
- TD 0.34
- VRTX 2.22
- Stochastic Oscillator
- TD 95.80
- VRTX 72.63
About TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 55% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 40% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.